GRAIL, Inc.

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
  • NextGen Class of 2017
1525 O’Brien Drive
Menlo Park, CA 94025
Stock Exchange: NASDAQ
Stock Symbol: GRAL
CEO: Bob Ragusa

  • Featured Employer
THE POWER OF US

To pursue a mission like GRAIL’s, it takes a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world.

Because we’ve set our sights high, the work we’re doing asks a lot of us. Pursuing scientific breakthroughs, scaling for growth, and driving change across a dynamic operating environment requires next-level creativity and collaboration. It takes agility, courage, curiosity, and humility. It takes tapping into our passion on a daily basis.

OUR VALUES

We navigate well in complexity and ambiguity

We anticipate what’s next, commit to clear actions and pivot as needed

We see change as an opportunity

We put on our GRAIL hat first to achieve our shared objectives

We bring in the right skills and team members to get the work done

We work with rigor and speed, and use data for unmatched solutions

We take on the problems others avoid

We bring the outside, in

We build the future with focused execution

We challenge the status quo and take intelligent risks

We step up to address difficult issues, saying what needs to be said

We readily tackle tough assignments and support others who do the same

We stay curious and share lessons learned

We listen and work to include diverse views

We test our assumptions and welcome debate

LIFE AT GRAIL
Everyone at GRAIL believes in our mission. It’s why we’re here. It’s what makes our company different from any other. We’re committed to changing the world, and when we believe in each other, there’s nothing we can’t do.
  • “Being around so many people who are so committed to this mission, it’s impossible to be in the same room with them and not feel that adrenaline, and not feed that need to rise above all of the different things that we might go through.”
    Shawnda Madison
  • “I heard about what GRAIL was trying to do, which was to develop a blood test for detecting any kind of cancer early, and it was like galling in love. Within five minutes, I was like, ‘I’m in.’”
    Tina Clarke Dur
  • “Everybody here just works so incredibly hard. And if you start to think about it, it is the mission that is at the core of what is driving our people to literally grind through the days, grind through the weeks, and really get this out to the masses.”
    Stephanie Guzman

We’re looking for smart, passionate people who embrace solving hard problems with urgency to help us achieve our mission.

Are you ready to join us?

View Job Openings

Welcome to The Cancer SIGNAL, a podcast presented by GRAIL.

On this monthly podcast, we explore topics relating to early cancer detection, including multi-cancer early detection testing, cancer genomics and risk, barriers to cancer screening, and much more.
NEWS
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
Last week, the Biden administration revealed the first drug prices negotiated under the Inflation Reduction Act; Lykos, Grail and others make substantial staffing cuts, and Pfizer/BioNTech see mixed results for their COVID/flu vaccine.
Following the recently completed spinoff of cancer detection company Grail, sequencing giant Illumina said Thursday it expects to absorb a $1.47 billion goodwill impairment charge.
Illumina on Monday announced that its board of directors is spinning off Grail and has applied to list the cancer diagnostics company on the Nasdaq.
After a years-long antitrust battle, the European Commission on Friday approved Illumina’s plans to divest Grail. However, Illumina said while there is “an agreement with the EC on specific divestment options” that “does not mean the method of divestment has been finalized.”
Research associates are always in demand. Check out these top companies currently hiring RAs.
The European Commission on Thursday ordered Illumina to divest Grail, opening the next chapter in the years-long regulatory saga. Illumina is reviewing the order, Reuters reported.
Francis deSouza resigned from Illumina’s helm after strong campaigning from activist investor Carl Icahn and the ongoing regulatory roadblocks facing the company’s acquisition of GRAIL.
JOBS
IN THE PRESS